Flow Cytometry in Oncology and Immunology Market to Grow with a CAGR of 8.19% through 2030
Rising expansion of flow cytometry for research
activities is expected to drive the growth of Global Flow Cytometry in Oncology
and Immunology market growth in the forecast period, 2026-2030.
According
to TechSci Research report, “Flow Cytometry in Oncology and Immunology
Market - Global Industry Size, Share, Trends, Competition, Opportunity,
and Forecast, 2030,” the Global Flow Cytometry in Oncology and
Immunology Market stood at USD 3.41 billion in 2024 and is anticipated to grow
with a CAGR of 8.19% in the forecast period through 2030. Flow cytometry
(FCM) is a multi-parameter analytical laboratory test for the characterization
of single cells and has been widely used in preclinical as well as in clinical
cancer immunotherapy studies. FCM is a technique of measuring the
number and characteristics of single cell that are flowing through a detector
system, using a fluorochrome-labeled monoclonal antibody.
Moreover, the growing prevalence of cancer cases, the
technological advancement with highest accuracy and precision, and the growing
awareness amongst population globally are projected to propel the growth of
market. However, the high cost of products of the flow cytometry equipment is
expected to hamper the growth of flow cytometry in oncology and immunology
market in the forecast years.
On the other hand, the development of more advanced
technologies includes mass cytometry, imaging flow cytometry, genomic
cytometry, and spectral cytometry with expanded ability to study immune
responses, by characterizing more cellular parameters simultaneously in single
cells with higher resolution. According to the researchers, the immune system
can target and destroy cancer cells, therefore, immune-oncology based therapies
cover different approaches to boost the immune response in cancer patients, that
range from activation of effector cells, vaccination with tumor antigens,
administration of oncolytic viruses, blockage of inhibitory pathways or
immunosuppressive mechanisms, use of adoptive chimeric antigen receptor T-cell
therapy, and to amplify the protective pathways.
Global
Flow Cytometry in Oncology and Immunology Market is segmented into type,
technology, offering, application, end user, regional distribution, and company.
Based on Offering, the Software category shows the fastest
growth in the Global Flow Cytometry in Oncology and Immunology Market. The
software segment is experiencing rapid expansion due to the increasing demand
for advanced data analysis tools capable of handling the complexity and volume
of flow cytometry data in oncology and immunology research. As flow cytometry
instruments become more sophisticated, generating high-dimensional data from
multiparametric assays, the need for robust, intelligent software solutions has
surged. These software platforms enable researchers and clinicians to
visualize, interpret, and share insights from cytometric datasets efficiently
and accurately. In oncology, flow cytometry software is vital for applications
such as tumor antigen profiling, minimal residual disease detection, and
immunotherapy monitoring. In immunology, the software aids in detailed immune
cell phenotyping, cytokine analysis, and studying immune responses to
infections, vaccines, and autoimmune conditions. Tools with artificial
intelligence (AI) and machine learning (ML) capabilities are becoming
increasingly popular, helping in automated gating, cluster analysis, and
pattern recognition, which significantly reduce analysis time and human error.
Based on
the Region, Asia Pacific shows the fastest growth in the Global Flow Cytometry
in Oncology and Immunology Market. The Asia Pacific region is witnessing rapid
advancements in healthcare infrastructure, increasing R&D investments, and
growing demand for precision diagnostics, all of which are driving the adoption
of flow cytometry in oncology and immunology. This growth is supported by both
governmental initiatives and the rising burden of cancer and immunological
disorders across countries like China, India, Japan, South Korea, and
Australia. One of the primary drivers is the rising prevalence of cancer in the
region. According to the World Health Organization (WHO), Asia accounted for
nearly half of the global cancer burden in 2022, with over 9 million new cancer
cases reported. Countries like India and China are experiencing a surge in
cancer-related healthcare demand, leading to increased investment in advanced
diagnostic tools, including flow cytometry platforms, which are vital for
immunophenotyping, tumor characterization, and monitoring therapeutic
responses.
The
leading companies operating in the global flow cytometry in oncology and
immunology market are:
- Danaher
Corporation
- Merck
KGaA
- Miltenyi
Biotec
- Neo-Genomics
Laboratories, Inc.
- Thermo
Fisher Scientific Inc.
- Cell
Signaling Technology, Inc.
- Becton,
Dickinson and Company
- Agilent
Technologies, Inc.
- DiaSorin
S.p.A
- OPKO
Health, Inc.
Customers
can also request for 10% free customization on this report.
“The global red biotechnology market is expected to witness substantial growth
in the coming years owing to the rising demand for personalized medicine,
expanding applications in gene therapy, and advancements in biopharmaceutical
manufacturing technologies. Increasing prevalence of chronic and genetic
diseases, coupled with the growing pipeline of biologics and vaccines, is
driving the adoption of red biotechnology across the pharmaceutical and
healthcare industries. Furthermore, rising investments in biomedical R&D
and the continued development of genetic engineering tools such as CRISPR-Cas9
are contributing to the expansion of this market. Additionally, the increased
approval rate of biopharmaceuticals and growing public and private funding
toward biotechnology innovation are further anticipated to fuel market demand
during the forecast period. Additionally, high market penetration rate of
technologically advanced immune-oncology therapies is expected to increase the
demand for flow cytometry in oncology and immunology market in the coming
years.”, said Mr. Karan Chechi, Research Director of TechSci Research, a
research based global management consulting firm.
“Flow Cytometry in Oncology and Immunology Market - Global Industry Size,
Share, Trends, Competition, Opportunity, and Forecast, Segmented By Type
(Immunology, Oncology), By Technology (Cell-Based Flow Cytometry, Bead-Based
Flow Cytometry), By Offering (Reagents, Instruments, and Consumables Software),
By Application (Translational Research, Clinical Research), By End User
(Hospitals, Diagnostic Laboratories, and Reference Laboratories, Pharmaceutical
and Biotechnology Companies, Academic Research Institutes, Contract Research
Organizations, and Others), By Region and Competition, 2020-2030F”, has evaluated the future growth
potential of Global Flow Cytometry in Oncology and Immunology Market and
provides statistics & information on market size, structure, and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Flow Cytometry in Oncology and
Immunology Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com